|Other Names||Complement C3, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, Complement C3 beta chain, C3-beta-c, C3bc, Complement C3 alpha chain, C3a anaphylatoxin, Acylation stimulating protein, ASP, C3adesArg, Complement C3b alpha' chain, Complement C3c alpha' chain fragment 1, Complement C3dg fragment, Complement C3g fragment, Complement C3d fragment, Complement C3f fragment, Complement C3c alpha' chain fragment 2, C3, CPAMD1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13691b was selected from the C-term region of C3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. C3-beta-c: Acts as a chemoattractant for neutrophils in chronic inflammation.|
|Tissue Location||Plasma. The acylation stimulating protein (ASP) is expressed in adipocytes and released into the plasma during both the fasting and postprandial periods|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Complement component C3 plays a central role in theactivation of complement system. Its activation is required forboth classical and alternative complement activation pathways.People with C3 deficiency are susceptible to bacterial infection.
Martinez-Barricarte, R., et al. J. Clin. Invest. 120(10):3702-3712(2010)Ruan, B.H., et al. J. Immunol. 185(7):4213-4222(2010)Luo, S., et al. J. Immunol. 185(4):2164-2173(2010)Zerbib, J., et al. Mol. Vis. 16, 1324-1330 (2010) :Johnatty, S.E., et al. PLoS Genet. 6 (7), E1001016 (2010) :
If you have any additional inquiries please email technical services at firstname.lastname@example.org.